SLU-PP-332 Query Orthography and ERR Pan-Agonist Pharmacology: A Research Review of Exercise-Mimetic Mechanism, CAS 303760-60-3 Identity, Catalogue Vocabulary Behind "slu pp peptide", "slupp-332", "is slu pp 332 a peptide" and "slu pp 332 tablets" Labels

By the Peptide Insider Research Desk · October 2026 · 10 min read

The catalogue token slu pp peptide and its many orthographic cousins—slupp-332, slu 332 peptide, slu pp32, slu po 332, slup peptide and the fully concatenated slupp332—all resolve to a single research-grade small molecule: SLU-PP-332 (CAS 303760-60-3), a synthetic pan-agonist of the estrogen-related receptor (ERR) family first reported by the Burris laboratory at Saint Louis University [1]. Despite its frequent appearance in peptide catalogues, SLU-PP-332 is not a peptide; it is a hydrazide-scaffold organic compound that targets nuclear receptors rather than cell-surface peptide receptors [1,2]. This review maps the orthographic variation behind queries such as what is slu pp 332 peptide, is slu pp 332 a peptide, is slu-pp-332 a peptide, what is slupp332 and what is slu pp 332 used for to the verified chemical identity, the ERRα/β/γ activation mechanism and the preclinical literature—strictly for research reference; not for human or veterinary use.

Query Orthography Crosswalk

Catalogue search logs reveal at least four classes of orthographic variation for SLU-PP-332. Each variant is catalogued below with its transcription mechanism and research-use-only (RUO) scope status. Queries such as how to take slu pp 332, how to take slu-pp-332, slu pp 332 how much to take, how much slu pp 332 to use, when to take slu pp 332, when to take slu-pp-332, slupp332 peptide dosage and slu pp 332 dosage per day pdf download free all request administration guidance that falls outside RUO scope and are therefore Declined from this crosswalk; the underlying compound identity is the same CAS 303760-60-3 discussed throughout this review.

No vendor listed above has been assessed or endorsed by this publication. Vendor-navigational strings are catalogued to document query patterns only.

Molecular Identity: Why SLU-PP-332 Is Not a Peptide

The query cluster is slu pp 332 a peptide and is slu-pp-332 a peptide recurs across catalogue search logs because the compound is frequently marketed alongside genuine peptide inventory. SLU-PP-332 is an acylhydrazide-class synthetic organic molecule with a molecular weight of 353.80 Da—well below the conventional peptide threshold of ~500 Da and lacking any amide-bonded amino acid residues [1,2]. Its development involved classical medicinal-chemistry structure–activity relationship (SAR) optimization around an oxazole-hydrazide scaffold, not solid-phase peptide synthesis [1]. The designator "PP" in the name derives from the Saint Louis University internal naming convention (SLU-PP = SLU-Pharmacological Probe), not from a peptide sequence abbreviation [1]. Queries such as what is slu pp 332 peptide, what is slu-pp-332 peptide and slu-pp-332 peptide injection therefore represent a class-mislabel pattern; the compound's nuclear-receptor mechanism is distinct from the cell-surface receptor pharmacology of genuine research peptides.

Mechanism of Action: ERRα/β/γ Pan-Agonism and PGC-1α Recruitment

SLU-PP-332 targets the three members of the estrogen-related receptor subfamily: ERRα (NR3B1), ERRβ (NR3B2) and ERRγ (NR3B3) [1]. Despite their nomenclature, these orphan nuclear receptors share no functional estrogen-binding capacity; they are constitutively active transcription factors whose activity is modulated by co-activator availability rather than hormonal ligands [1,3]. Upon binding the ERR ligand-binding domain, SLU-PP-332 stabilises the active conformation of helix 12, enhancing recruitment of the master co-activator peroxisome proliferator-activated receptor gamma co-activator 1-alpha (PGC-1α) to ERR-response elements (ERREs) in target gene promoters [1,3].

The downstream transcriptional programme encompasses three principal gene clusters [1,4]:

• Mitochondrial biogenesis: upregulation of electron transport chain (ETC) subunits and mitochondrial transcription factor A (TFAM), increasing organelle density.
• Fatty acid oxidation (FAO): induction of carnitine palmitoyltransferase 1 (CPT1) and medium-chain acyl-CoA dehydrogenase (MCAD), shifting substrate utilisation from glucose toward lipids.
• TCA cycle flux: enhanced expression of citrate synthase and isocitrate dehydrogenase isoforms, accelerating oxidative phosphorylation throughput.

This coordinated gene programme recapitulates the transcriptional signature observed in skeletal muscle following aerobic endurance training—the basis for the "exercise mimetic" descriptor applied to SLU-PP-332 in the literature [1,4]. Notably, ERR agonism also regulates autophagy through transcription factor EB (TFEB), linking the pathway to cellular quality-control mechanisms beyond energy metabolism [5].

Preclinical Evidence Table

Pharmacokinetic Limitations and Successor Compounds

SLU-PP-332 exhibits poor oral bioavailability in rodent models, necessitating parenteral administration in most published studies [1,11]. This limitation prompted the development of SLU-PP-915, a structurally optimised successor with enhanced oral absorption characteristics [11]. The chemical optimisation programme reported by Okda et al. (2026) explored SAR modifications around the hydrazide core, yielding analogues with improved metabolic stability while retaining ERRα/β/γ selectivity [2]. These pharmacokinetic constraints are relevant to the catalogue queries slu pp 332 tablets and slu pp 332 powder, which imply oral formulation availability—a format that remains experimental for this compound class. Queries referencing slu-pp-332 peptide injection likewise conflate peptide reconstitution workflows with small-molecule parenteral administration.

The "Benefits" Query Pattern

The search string benefits of slu pp 332 recurs at moderate volume. In RUO context, the preclinical observations documented above—enhanced oxidative capacity, improved insulin sensitivity in diet-induced obesity models, cardiac protection in pressure-overload models and reduced renal inflammation in ageing tissue—represent experimentally observed signal vectors, not therapeutic benefits [1,4,6,7]. No human efficacy data exist, and no regulatory agency has approved SLU-PP-332 for any indication [1]. The compound is not listed on the FDA 503A bulk drug substances list and is not legally available through compounding pharmacy channels for human administration.

Frequently Asked Questions

What is slu pp 332 peptide?

SLU-PP-332 (CAS 303760-60-3) is a synthetic hydrazide small molecule, not a peptide. It functions as a pan-agonist of estrogen-related receptors ERRα, ERRβ and ERRγ and was developed at Saint Louis University as a pharmacological probe for exercise-mimetic research [1].

Is slu pp 332 a peptide?

No. SLU-PP-332 is a 353.80 Da organic molecule built on an oxazole-hydrazide scaffold. It contains no amino acid residues and is synthesised by classical medicinal chemistry, not solid-phase peptide synthesis. It appears in peptide catalogues because vendors sell it alongside genuine peptide inventory [1,2].

What is slu pp 332 used for in research?

In preclinical models SLU-PP-332 is used as a chemical probe to activate ERR-mediated gene programmes that mimic aerobic exercise adaptations—including mitochondrial biogenesis, fatty acid oxidation and oxidative fibre-type switching—without physical training. All published data are from rodent or in vitro studies [1,4].

What does slu-pp-332 peptide injection refer to?

The query conflates peptide reconstitution language with small-molecule administration. SLU-PP-332 is not a peptide and is not reconstituted from lyophilised powder in the same manner as research peptides. In published rodent studies, it was administered by intraperitoneal injection in a vehicle solution, not via the subcutaneous protocols typical of peptide research [1].

What are the benefits of slu pp 332 observed in preclinical research?

In rodent models, SLU-PP-332 administration has been associated with enhanced treadmill endurance, reduced fat mass, improved insulin sensitivity, preserved cardiac ejection fraction under pressure overload and reduced renal inflammation in ageing tissue. These are experimental observations, not therapeutic claims, and no human trials have been conducted [1,4,6,7].

Where to Source SLU-PP-332 for Research

Investigators seeking SLU-PP-332 for in vitro or preclinical studies should evaluate supplier documentation for certificate-of-analysis (CoA) completeness, HPLC purity reporting and mass-spectrometry identity confirmation. Short Chain Aminos maintains a research-compound catalogue with CoA-backed purity data. Additional suppliers with documented analytical verification include BioPep, Catalyst Research and Apex Research Services. No vendor listed has been assessed or endorsed by this publication; sourcing decisions should be guided by independent analytical verification of lot-specific CoA documentation.

Works Cited

1. Billon C, et al. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chem Biol. 2023;18(4):756–765. PMID: 36988910.
2. Okda HE, et al. Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor pharmacology. J Med Chem. 2026. PMID: 41850449.
3. Losby M, et al. The Estrogen Receptor-Related Orphan Receptors Regulate Autophagy through TFEB. Mol Pharmacol. 2024;106(3). PMID: 39168657.
4. Billon C, et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Clin Invest. 2024;134(2). PMID: 37739806.
5. de Souza-Lima J, et al. Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications. Rev Med Chil. 2026;154(2). PMID: 42024694.
6. Xu W, et al. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation. 2024;149(3):227–250. PMID: 37961903.
7. Wang XX, et al. Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney. Am J Pathol. 2023;193(12):1935–1952. PMID: 37717940.
8. Bonanni R, et al. Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study. Front Physiol. 2025;16:1562780. PMID: 40692696.
9. Avliyakulov NK, et al. Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist. Drug Test Anal. 2026. PMID: 41688415.
10. Möller T, et al. In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential. Rapid Commun Mass Spectrom. 2026;40(8). PMID: 41588687.
11. Billon C, et al. An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. J Pharmacol Exp Ther. 2026;396(1). PMID: 41421047.

This article is provided strictly for research reference and informational purposes. It does not constitute medical advice, dosing guidance or encouragement to use any compound for human or veterinary applications. All experimental observations cited above derive from rodent or in vitro models. SLU-PP-332 is an experimental research tool compound with no approved human indication. Researchers should consult institutional review frameworks before initiating any investigation.